CAMBRIDGE, Mass., Jan. 6, 2026 /PRNewswire/ -- ARTBIO, Inc. ("ARTBIO"), a clinical-stage radiopharmaceutical company developing a new class of 212Pb alpha radioligand therapies (ARTs), announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback